Notably, in 2020, lenalidomide combined with tafasitamab (a CD19 targeting mAb) received accelerated approval for patients with R/R diffuse large B-cell lymphoma (DLBCL) (28). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.